Pharmafile Logo
Pharmafocus logo
Advanced Search

myeloma

Showing 15 posts of 33 posts found.

Revlimid image

Celgene gets FDA licence extension for myeloma drug

February 19, 2015
Sales and Marketing Celgene, FDA, Revlimid, lenalidomide, myeloma

The FDA has given Celgene an extended licence for its multiple myeloma drug Revlimid (lenalidomid), to include people who are …

News
Celgene image

Celgene’s blood cancer pill too expensive for NHS

February 13, 2015
Sales and Marketing Celgene, NHS, NICE, Pomalidomide, imnovid, myeloma

NICE has decided not to recommend Celgene’s Imnovid for treating patients with multiple myeloma – a cancer that affects white …

News
Onyx pharma image

Treatment shifts away from chemotherapy for multiple myeloma

December 10, 2014
Research and Development, Sales and Marketing Kyprolis, carfilzomib, chemotherapy, myeloma, onyx pharmaceuticals

Results from a Phase III study of a new multiple myeloma offering have found promising results for a treatment that …

News

Priority review for Novartis myeloma drug

November 26, 2014
Sales and Marketing FDA, Farydak, Novartis, daratumumab, elotuzumab, myeloma, odac

Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …

News

Future bleak for Novartis’ myeloma drug

November 21, 2014
Medical Communications FDA, Farydak, Novartis, ixazomib, myeloma, panobinostat

Novartis suffered a major disappointment with the negative FDA panel vote for multiple myeloma candidate Farydak earlier this month, but …

News
News image

The numbers game: getting quantitative information to patients

November 17, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kadcyla, Les Rose, clinical, myeloma, numbers, numerics

The great physicist Lord Kelvin said: “If you can measure something, and express it in numbers, then you know something …

Feature
Caner image

More cancer patients surviving for longer

October 31, 2014
Medical Communications, Research and Development, Sales and Marketing Cancer, bladder, breast, myeloma, oncology, ons, prostate

Cancer survival rates in England are continuing to improve, though many cancers still have an ‘extremely poor’ prognosis, according to …

News
amgen image

Amgen cancer drug fails key test

August 14, 2014
Sales and Marketing Amgen, Cancer, Kyprolis, myeloma

Amgen’s new rare cancer drug has failed in a late-stage trial just a year after the US biotech spent $10.4 …

News
Celgene image

Scottish Medicines Consortium disappoints Celgene

July 8, 2014
Sales and Marketing Celgene, SMC, Scottish Medicines Consortium, imnovid, myeloma

Celgene admitted it is ‘disappointed’ with the Scottish Medicines Consortium decision not to recommend blood cancer therapy Imnovid for patients …

News
bms_close_logo

BMS and AbbVie get FDA lift

May 21, 2014
Research and Development, Sales and Marketing AbbVie, BMS, FDA, elotuzumab, multiple, myeloma

Bristol-Myers Squibb and AbbVie are celebrating after receiving breakthrough designation status from the US regulator for their investigational medicine elotuzumab …

News
Low image

How can ‘innovation’ be defined?

April 14, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, NHS, UK, eric low, innovation, myeloma

Innovation has been and continues to be an important topic of discussion for a number of different stakeholders and disciplines …

Feature
celgene_1_02_4

Celgene ‘stops Mylan entering market’

April 6, 2014
Sales and Marketing Celgene, Mylan, Revlimid, myeloma

Generic manufacturer Mylan is suing Celgene in a spat over allowing copycat versions of existing cancer drugs – Revlimid and …

News
Velcade image

NICE approves Velcade

March 21, 2014
Sales and Marketing Janssen, NHS, NICE, Velcade, myeloma

NICE has recommended Janssen’s proteasome inhibitor Velcade as an induction treatment for some patients with newly-diagnosed multiple myeloma. The draft …

News
ABPI image

Regulate, don’t strangulate

January 6, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, code of practise, low, myeloma

As many of you will know, work is now under way to revise the ABPI Code. Not before time I …

Feature
Eric Low image

Trials and tribulations

October 14, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, NHS, eric low, myeloma, transparency

I have been chief executive of Myeloma UK since its inception 17 years ago, and its unique bedside to bench …

Feature
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025